Evercore ISI Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $425.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective boosted by equities research analysts at Evercore ISI from $385.00 to $425.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “in-line” rating on the medical equipment provider’s stock. Evercore ISI’s target price would indicate a potential downside of 2.51% from the stock’s current price.

ISRG has been the subject of several other reports. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. The Goldman Sachs Group began coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Jefferies Financial Group lifted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Piper Sandler boosted their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. Finally, Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $404.79.

Intuitive Surgical Trading Down 0.1 %

Shares of NASDAQ:ISRG traded down $0.29 during trading on Tuesday, reaching $435.95. The company had a trading volume of 358,639 shares, compared to its average volume of 1,518,843. The company has a fifty day moving average of $403.83 and a two-hundred day moving average of $383.50. The stock has a market capitalization of $154.63 billion, a P/E ratio of 78.69, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $448.10.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.00 EPS. As a group, equities research analysts predict that Intuitive Surgical will post 4.8 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total value of $589,484.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock valued at $6,927,011 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in Intuitive Surgical by 0.3% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after acquiring an additional 27 shares during the last quarter. Advance Capital Management Inc. raised its holdings in Intuitive Surgical by 3.8% in the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 27 shares during the last quarter. Perigon Wealth Management LLC raised its holdings in Intuitive Surgical by 0.5% in the 1st quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after acquiring an additional 27 shares during the last quarter. Sugarloaf Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 5.7% during the 1st quarter. Sugarloaf Wealth Management LLC now owns 534 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 29 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC increased its holdings in shares of Intuitive Surgical by 1.3% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock worth $751,000 after buying an additional 29 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.